Idera Pharmaceutical (IDRA) 1.92 $IDRA Idera

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Idera Pharmaceutical (IDRA) 1.92 $IDRA

Idera Pharmaceuticals Presents the Novel Mechanism of Action of its Third Generation Antisense Technology
GlobeNewswire - Wed Aug 24, 6:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform.
IDRA: 1.92 (unch)

Idera to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Fri Aug 12, 8:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will provide a corporate overview and participate in a fireside chat discussion at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 12:45 p.m. Eastern Time at the Le Parker Meridien Hotel in New York City.
IDRA: 1.92 (unch)

Idera Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Tue Aug 02, 6:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2016.
IDRA: 1.92 (unch)

Idera Pharmaceuticals (IDRA) Catches Eye: Stock Rises 8.3%
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:41AM CDT
Idera Pharmaceuticals, Inc. (IDRA) shares rose over 8% in the last trading session.
IDRA: 1.92 (unch), ANIP: 59.86 (-1.56)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.53 (-0.06), BIIB: 313.59 (+7.56), IDRA: 1.92 (unch), RTRX: 16.10 (-0.25), LGND: 106.19 (-0.85), ACOR: 24.27 (-0.07)

Idera to Present at Two June Investor Healthcare Conferences
GlobeNewswire - Tue Jun 07, 8:00AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Medical Officer, Joanna Horobin, M.B., Ch.B. will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 4:00 p.m. Eastern Time at the Grand Hyatt in New York City.
IDRA: 1.92 (unch)

Idera reports 1Q loss
Automated Insights - Mon May 09, 3:45PM CDT
CAMBRIDGE, Mass. (AP) _ Idera Pharmaceuticals Inc. (IDRA) on Monday reported a loss of $12.8 million in its first quarter.
IDRA: 1.92 (unch)

Idera Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Mon May 09, 3:00PM CDT
9 of 10 Waldenstrom's Macroglobulinemia Patients Treated at the Highest Dose have Demonstrated Reductions in IgM or M-Protein Levels in Ongoing Trial
IDRA: 1.92 (unch)

Idera to Release 2016 First Quarter Results on May 9, 2016
GlobeNewswire - Thu May 05, 6:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced that first quarter results for 2016 are expected to be released on Monday, May 9, 2016 after the close of the U.S. Financial Markets.
IDRA: 1.92 (unch)

Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity from Combination Treatment with Intra-tumoral IMO-2125 and IDO-1 Inhibitor at AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 6:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced new preclinical data demonstrating enhanced systemic anti-tumor activity in preclinical cancer models with intra-tumoral administration of IMO-2125 in combination with an inhibitor of the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO1). IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera. IDO is one of several immune checkpoints involved in tumor immune escape. IDO-1 inhibitors are currently in clinical development. These data are being presented at the AACR Annual Meeting 2016 in New Orleans, LA.
IDRA: 1.92 (unch)

Idera to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 11, 9:30AM CDT
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will present at the 15 Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:40 p.m. Eastern Time at the Westin Grand Central Hotel in New York City.
IDRA: 1.92 (unch)

Global Idera Pharmaceuticals, Inc. Market Overview Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:13AM CST
'IDERA PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the IDERA PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
IDRA: 1.92 (unch)

Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.73 (+0.02), IMMU: 2.74 (+0.06), INCY: 82.02 (+1.21), IMGN: 2.75 (-0.05), AMGN: 169.77 (-0.36), EPZM: 7.16 (-0.15), BIND: 0.78 (-0.09), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CTIC: 0.39 (unch), IDRA: 1.92 (unch), CYCC: 5.71 (unch), GILD: 76.89 (-0.53), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), CBMG: 13.94 (-0.55), CELGZ: 1.18 (+0.05)

Global Moderate Psoriasis Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Feb 03, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/svzcsv/moderate) has announced the addition of the "Moderate Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Moderate Psoriasis Overview - Therapeutics Development - Pipeline Products for Moderate Psoriasis - Overview - Pipeline Products for Moderate Psoriasis - Comparative Analysis - Moderate Psoriasis - Therapeutics under Development by Companies - Moderate Psoriasis - Therapeutics under Investigation by Universities/Institutes - Moderate Psoriasis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Moderate Psoriasis - Products under Development by Companies - Moderate Psoriasis - Products under Investigation by Universities/Institutes - Moderate Psoriasis - Companies Involved in Therapeutics Development - AbGenomics International, Inc. - ADC Therapeutics Sarl - Almirall, S.A. - AstraZeneca Plc - Avexxin AS - Boehringer Ingelheim GmbH - Celgene Corporation - Convoy Therapeutics, Inc. - Crescendo Biologics Limited - Delenex Therapeutics AG - Eli Lilly and Company - Forward Pharma A/S - Galectin Therapeutics, Inc. - GlycoMar Limited - Idera Pharmaceuticals, Inc. - Johnson & Johnson - Merck KGaA - OPKO Health, Inc. - Sandoz International GmbH - Soligenix, Inc. - Sun Pharma Advanced Research Company Ltd. - Syntrix Biosystems, Inc. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/svzcsv/moderate
JNJ: 119.32 (+0.24), IDRA: 1.92 (unch), OPK: 9.33 (+0.04), FWP: 19.13 (+0.05), AZN: 33.31 (+0.71), GALT: 1.70 (+0.05), LLY: 76.85 (-0.38), VRX.TO: 37.34 (-0.75), CELGZ: 1.18 (+0.05)

Waldenstrom Macroglobulinemia Therapeutics Development Pipeline Review, H2 2015
M2 - Wed Jan 27, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/v6dn7v/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Waldenstrom Macroglobulinemia Overview - Therapeutics Development - Pipeline Products for Waldenstrom Macroglobulinemia - Overview - Pipeline Products for Waldenstrom Macroglobulinemia - Comparative Analysis - Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies - Waldenstrom Macroglobulinemia - Therapeutics under Investigation by Universities/Institutes - Waldenstrom Macroglobulinemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Waldenstrom Macroglobulinemia - Products under Development by Companies - Waldenstrom Macroglobulinemia - Products under Investigation by Universities/Institutes - Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - BeiGene(Beijing) Co.,Ltd - Calithera Biosciences, Inc. - Celgene Corporation - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - IGF Oncology, LLC. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/v6...aldenstrom
INCY: 82.02 (+1.21), IDRA: 1.92 (unch), GILD: 76.89 (-0.53), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), CELGZ: 1.18 (+0.05), KPTI: 10.62 (-0.48)

Forget Inovio Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys
Keith Speights, The Motley Fool - Motley Fool - Tue Jan 26, 3:40PM CST
Image Source: Inovio Pharmaceuticals. Sure, the future for the DNA immunotherapies under development by Inovio Pharmaceuticals (NASDAQ: INO) seems very promising. But after a year when Inovio's shares dropped nearly 28%, some investors might be...
INO: 9.08 (-0.06), CARA: 5.32 (-0.06), IDRA: 1.92 (unch), AZN: 33.31 (+0.71)

Why Shares in Idera Pharmaceuticals, Inc. Dropped 10% Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Jan 15, 2:51PM CST
Image source: Idera Pharmaceuticals. W hat: After presenting at the J.P. Morgan healthcare conference on Wednesday and hitting a new 52-week low yesterday, shares in Idera Pharmaceuticals   slumped by another 10% earlier today. So what: The...
IDRA: 1.92 (unch)

Why Idera Pharmaceuticals Inc. Shares Dropped 36% in 2015
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 13, 6:18AM CST
What: Shareholders of Idera Pharmaceuticals , a clinical-stage biopharmaceutical company focused on cancer and other rare diseases, had a rough 2015. The company's shares lost more than 36% of their value in during the year, according to data from...
IDRA: 1.92 (unch), GSK: 44.26 (+1.28)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 111

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 36

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 358

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 288

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 438

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 395

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 343

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
rshangout.com/blog/news?page=2">More News Articles